Key Words: pannexins Ⅲ phenylephrine Ⅲ adrenergic receptor Ⅲ smooth muscle cells Ⅲ vasoconstriction I n resistance arteries, the coordination of vascular smooth muscle cell (VSMC) constriction helps to regulate blood flow and peripheral resistance and thus overall blood pressure. 1 Although it has been hypothesized that gap junctions link VSMCs in resistance arteries to provide this coordination, the gap junctional coupling of VSMCs is controversial, 3 and the presence of gap junctions and the gap junction proteins (connexins) is difficult to observe. 4 Thus, VSMCs may use other mechanisms to communicate and coordinate their responses.
I n resistance arteries, the coordination of vascular smooth muscle cell (VSMC) constriction helps to regulate blood flow and peripheral resistance and thus overall blood pressure. 1 Although it has been hypothesized that gap junctions link VSMCs in resistance arteries to provide this coordination, the gap junctional coupling of VSMCs is controversial, 3 and the presence of gap junctions and the gap junction proteins (connexins) is difficult to observe. 4 Thus, VSMCs may use other mechanisms to communicate and coordinate their responses.
Pannexins (Panx) are tetra-spanning membrane proteins that mediate paracrine intercellular communication via release of purines such as ATP or UTP. 5, 6 The physiological function of Panx remains poorly documented in the vasculature, where there is currently no indication of Panx expression or function. We thus hypothesized that pannexins may coordinate VSMC constriction through the release of purines and activation of purinergic receptors.
Electron Microscopy
Thoracodorsal resistance arteries (TDAs) were immunolabeled with Panx1 antibody and 10-nm gold beads and imaged with a JEOL 6400 scanning electron microscope.
Vessel Transfection
The VSMCs of TDAs were transfected with either a plasmid that contained Panx1-green fluorescent protein or Panx1 small interfering RNA and were cultured for 16 to 18 hours.
Coimmunoprecipitation
Panx1 or ␣1D-adrenergic receptor antibody was conjugated to Dynabeads, incubated with TDA lysates, and run on an SDS-PAGE gel.
Statistical Analysis
One-way or 2-way ANOVA, followed by a Bonferroni test, was used for comparisons between treatments. PϽ0.05 was significant.
Results

Panx1 Is Expressed in VSMCs of TDAs
Using transmission electron microscopy, we could not observe gap junctions between VSMCs in TDAs but could clearly identify tight junctions between endothelial cells (ECs; Figure 1A ). The absence of membrane apposition was confirmed in other resistant arteries, whereas gap junctions could be observed between VSMCs in mouse aorta (Online Figure I ). Therefore, we tested for the presence of the 3 Panx isoforms in TDA. Using Western blot ( Figure 1B ) and immunolabeling, we could only identify Panx1, both in ECs and VSMCs and between VSMCs ( Figures 1C-E) . In mouse aorta, we could not detect any Panx isoform in the VSMCs (Online Figure I) . Immuno-scanning electron microscopy on TDAs with an extracellular loop Panx1 antibody revealed the presence of the protein on the VSMC plasma membrane ( Figure 1F ).
Phenylephrine-Induced Constriction Is Mediated by Panx
The data above clearly demonstrate that Panx1 is expressed in VSMCs; however, its functional role in the resistance arteries is unknown. We therefore constructed dose-response curves using the ␣1-adrenergic receptor agonist phenylephrine in the presence of 3 Panx inhibitors: mefloquine 7 (Figure 2A) , 10 Panx1 peptide 8, 9 ( Figure 2B ), and probenecid 6,9 ( Figure 2C ). Panx inhibitors all significantly reduced phenylephrine-induced vasoconstriction Figure IV) . The Panx channels release purines, 5, 6 which induce constriction when applied to TDA (Online Figure IV) . We thus tested the effect of apyrase, an ectonucleotidase that degrades purines. Both 1 and 10 U/mL significantly reduced TDA constriction in response to phenylephrine ( Figure 2D calized on ECs, we perfused probenecid, apyrase, and reactive blue-2 in the lumen of TDAs and found no changes in phenylephrine responses, a result consistent with experiments on endothelium-denuded TDAs in which probenecid inhibited phenylephrine-induced constriction to the same extent as observed on intact TDAs (Online Figure V) . Lastly, cultured VSMCs from coronary resistance arteries (expressing both ␣1D-adrenergic receptor and Panx1) had significant increases in ATP release after phenylephrine stimulation that was inhibited by 10 Panx1, whereas cultured aortic VSMCs (expressing only ␣1D-adrenergic receptor) and normal rat kidney cells (which do not express ␣1D-adrenergic receptor or Panx1) did not have any increase in ATP release after phenylephrine stimulation (Online Figure VI) .
Modulation of Panx1 Expression Modifies Phenylephrine-Induced Constriction of TDAs
TDAs were transfected either with Panx1-green fluorescent protein or with Panx1 small interfering RNA (Online Figure VII) . When Panx1 was overexpressed, the response of TDAs to phenylephrine was increased by approximately 30%, whereas underexpression of Panx1 induced a 45% decrease in constriction in response to phenylephrine ( Figure 3A ; Online Figure VIII) . Transfection of TDAs with control small interfering RNA did not affect phenylephrine-induced constriction (Online Figure VII) . Immunolabeling of transfected TDAs revealed that Panx1 expression was modified only in VSMCs and not in ECs ( Figure 3B ), which was confirmed with an anti-green 
Panx1 Is Associated With ␣1-Adrenergic Receptor and Is Not Involved in KCl Constriction
We investigated whether Panx inhibitors could alter a receptor-independent stimulus such as KCl. We tested the 3 different Panx inhibitors and the purinergic inhibitors and found that none of them affected TDA constriction in response to KCl ( Figure 4A ). We thus hypothesized that a specific interaction may occur between Panx1 and ␣1D-adrenergic receptor, the primary adrenergic receptor responsible for VSMC constriction (Online Figure X) . Immunolabeling of TDAs with Panx1 and ␣1D-adrenergic receptor antibodies revealed colocalization of the 2 proteins ( Figures 4B and 4C) . The association between Panx1 and ␣1D-adrenergic receptor was confirmed by coimmunoprecipitation from TDA lysates ( Figure 4D ).
Discussion
In the microcirculation, coordination of VSMC contraction is essential for the regulation of blood flow distribution and peripheral vascular resistance. Gap junctions are likely responsible for VSMC coordination in conduit arteries; however, their role in VSMC coordination in resistance arteries remains unclear. 4 Our transmission electron microscopy results indicate that VSMCs of TDAs are unlikely to be coupled exclusively via gap junctions, because the VSMCs are separated by relatively large intercellular spaces. The close apposition of EC plasma membranes, characteristic of gap junctions, indicates that the intercellular space observed between VSMCs was not an artifact of fixation. Our demonstration of Panx1 expression could suggest a mechanism that allows VSMCs to coordinate their responses independent of gap junctions.
Pannexin channels release purines in response to different stimuli. 5 In the vasculature, the concentration of purines is finely regulated by ectonucleotidase at the surface of VSMCs and contributes to local regulation of vascular tone. 10 Our findings suggest that Panx1, purines, and purinergic receptors are involved in TDA constriction in response to phenylephrine. However, we also found staining for Panx1 in ECs, which are known to release ATP, 11 although our data show that the inhibition of phenylephrine responses was not due to Panx1 in ECs. Nevertheless, Panx1 expression in ECs suggests that Panx1 could be involved in EC functions such as vasodilation or inflammatory cell adhesion.
The present data imply that Panx1 is specifically involved in phenylephrine-induced, but not KCl-induced constriction. This suggests that Panx1 is not activated solely by the rise of intracellular calcium concentrations or mechanical stretch. 5 Reports from cell culture studies have suggested that purine release through Panx1 may occur after activation of G q/11 -coupled ␣1-adrenergic receptor but not after stimulation of G i/o -coupled ␣2-adrenergic receptors or G s -coupled ␤-adrenergic receptors. 12 Thus, Panx1 could also be involved in TDA constriction in response to other G q/11 -coupled receptor agonists, such as serotonin, endothelin-1, or angiotensin II. However, our evidence indicates that Panx1 and ␣1D-adrenergic receptor are closely associated at the protein level, which suggests that Panx1 and the ␣1-adrenergic receptor may be part of a signaling microdomain.
The present data provide the first demonstration of Panx expression in the vasculature and of its function in the control of vasoconstriction. Our results suggest that the release of purines through Panx1 channels on VSMCs is triggered by phenylephrine stimulation and participates in control of vascular tone through purinergic receptors ( Figure 4D ). Thus, Panx1 could contribute to the coordination of VSMC constriction and the regulation of blood pressure via catecholamines released by sympathetic nerves.
Novelty and Significance
What Is Known?
• Intercellular communication between smooth muscle cells (SMCs) within the vascular wall is essential for the control of vasoreactivity, but the mechanism for this remains unclear.
• Pannexin channels participate in intercellular communication through the release of purines such as ATP, a potent vasoconstrictor.
What New Information Does This Article Contribute?
• Pannexin1 (Panx1) is present in the SMCs of resistant arteries and plays a role in phenylephrine-induced vasoconstriction.
• Panx1 and the ␣1D-adrenergic receptor are part of the same protein complex.
• When phenylephrine binds to the ␣1D-adrenergic receptor, Panx1 opens to release purines that can act on purinergic receptors present on SMCs to enhance phenylephrine-induced vasoconstriction.
Intercellular communication between SMCs serves to regulate the vasoconstriction of resistance arteries, a fundamental process for the control of blood flow and peripheral resistance; however, the exact mechanisms of SMC communication remain unclear. Here, we focused on Panx1, a protein known to participate in the release of ATP that has not been described in the vasculature. Our data indicate that Panx1 releases ATP during contraction of resistance arteries in response to phenylephrine, thereby controlling the intensity of vasoconstriction. These data are the first to describe the presence of, and a role for, Panx1 in the vascular wall, providing a novel mechanism for SMC communication.
Supplementary methods
Western blot
Thoracodorsal arteries (TDA) from 4 mice were homogenized on ice in lysis buffer containing Tris-HCl 50 mmol/L, NaCl 150 mmol/L, EDTA 5 mmol/L, sodium deoxycholate 1%, Triton X-100 0.5%, Na 3 VO 4 500 µmol/L, AEBSF 10 µmol/L, NaF 10 mmol/L, in PBS and pH adjusted to 7.4. Protein lysates were sonicated and subjected to electrophoresis on 4-12 % Bis-Tris gels (Invitrogen), transferred to nitrocellulose, and visualized and analyzed using Li-Cor Odyssey Imager as previously described 1 .
Immunofluoresence
Mice were deeply anesthetized with pentobarbital (40 mg/kg) and perfused transcardially with 5 ml of heparinized phosphate-buffered saline (PBS) followed by 5 ml of 4 % paraformaldehyde in PBS. TDA were isolated, placed in 4 % paraformaldehyde for 1 hour and then placed in 70 % ethanol for further paraffin embedding. Paraffin was removed and sections were subjected to immunohistochemistry as previously described 2 . For double immunolabelling experiments, sections were first incubated with Panx1 antibody and the secondary antibody coupled to Alexa Fluor 543. Sections were then incubated with the blocking solution for 6 hours and with α1D-adrenoreceptor antibody followed by incubation with the secondary antibody coupled to Alexa Fluor 647. Imaged for the double immunostaining were captured with a Zeiss LSM 700.
Electron microscopy
Ultrastructure electron microscopy Mice were deeply anesthetized with pentobarbital (40 mg/kg) and perfused transcardially with 5 ml of heparinized phosphate-buffered saline (PBS) followed by 5 ml with 4% paraformaldehyde and 2 % glutaraldehyde in PBS. Thoracodorsal arteries were isolated and ultrastructure TEM images were obtained as previously desribed 1 .
Immunolabeling on TEM sections
Mice were deeply anesthetized with pentobarbital (40 mg/kg) and perfused transcardially with 5 ml of heparinized phosphate-buffered saline (PBS) followed by 5 ml with 4 % paraformaldehyde and 0.5 % glutaraldehyde in PBS. Thoracodorsal arteries were isolated and processed for ultrathin sections and immunogold labeling as previously described 3 . For double immunolabelling experiments, sections were first incubated with Panx1 antibody and the secondary antibody coupled to 25 nm gold beads. Sections were then incubated with the blocking solution for 6 hours and with α1D-adrenoreceptor antibody followed by incubation with the secondary antibody coupled to 10 nm beads. Immunolabeling coupled to SEM Mice were deeply anesthetized with pentobarbital (40 mg/kg) and perfused transcardially with 5 ml of heparinized phosphate-buffered saline (PBS) followed by 5 ml of 4 % paraformaldehyde and 0.5 % glutaraldehyde in PBS. Thoracodorsal arteries were isolated and placed for 30 minutes in 4 % paraformaldehyde and 0.5 % glutaraldehyde at 4°C. After a quick wash in PBS, adventitia was removed in 2 steps: first the vessels were treated with 1 mg/mL collagenase type VIII (Sigma) supplemented with 55 ug/mL CaCl 2 in PBS at 37°C for 4 hours on a shaker; second, after a quick wash in PBS, vessels were placed in 30 % KOH in PBS and heated at 60°C for 4 minutes. Vessels were then subjected to immunolabeling following the same protocol used for immunolabeling on TEM sections except that samples were not permeabilized. Vessels were fixed with 1% osmium tetraoxyde for 1 hour, and after a quick wash in PBS, vessels were successively dehydrated in 40%, 60%, 80% and 100% ethanol for 10 minutes each following a final dehydration using the critical point dryer. Finally, vessels were coated with gold and imaged using a JEOL 6400 scanning electron microscope.
Vessel Cannulation:
Mice were sacrificed with an overdose of pentobarbital (60-90 mg/kg) injected intraperitonealy. First order thoracodorsal arteries (TDA) were isolated (with an internal diameter of approximately 200-250 µm) and placed in Krebs-HEPES buffer 4 . Arteries were cannulated at both ends with glass micropipettes and secured with 10-0 nylon suture in a pressure myograph (Danish MyoTechnology). The chamber was superfused with Krebs-Hepes solution, gassed with air, and maintained at 37°C while the vessel was perfused with Krebs-HEPES supplemented with 1% BSA. Vessels in the denuded ("-E") groups were perfused with air for 5-10 minutes. Vessels were maintained in a no-flow state and held at a constant transmural pressure of 80 mmHg equivalent to the transmural pressure of these vessels in vivo 5, 6 . Vessels were allowed to equilibrate for 30 minutes before stimulation either with cumulative concentrations of phenylephrine (10 -8 to 10 -4 mol/L), ATP (10 -8 to 10 -3 mol/L) or a single dose of KCl (40 mmol/L). When indicated, drugs were applied to the vessel during the equilibration period and the initial diameter was determined at the end of this equilibration period. Integrity of endothelial function was assessed at the end of each agonist-induced constriction using 10 µmol/L acetylcholine. To determine whether the smooth muscle function was fully intact in the endothelium denuded groups ("-E") compared to the intact groups ("E"), vessels were superfused with 40 mM KCl solution for 20 minutes.
Vessel transfection
Mice were sacrificed with an overdose of pentobarbital (60-90 mg/kg) injected intraperitonealy. Thoracodorsal arteries were isolated and placed in RPMI media supplemented with penicillin (2mM)/streptomycin (50 U/mL) (Gibco) and CaCl 2 (2mmol/L). The TDA were then transferred to a cuvette containing 100 µl of Nucleofector solution (Lonza) complemented either with 5 µg of a plasmid containing a Panx1-GFP construct previously described 7 , 10 nmol/L of siRNA targeting Panx1 (Ambion) or 10 nmol/L of control siRNA (Thermoscientific). The cuvette was placed in the Nucleofector cuvette holder and subjected to electroporation (program A033). Arteries were then placed in RPMI supplemented with penicillin (2mM)/streptomycin (50 U/mL) (Gibco), CaCl 2 (2mmol/L) and BSA 1% in an incubator for 14 to 18 hours. After incubation, TDA were cannulated and pressurized at 40 mmHg for 15 minutes and then at 80 mmHg for 15 minutes before performing dose response to PE.
Co-immunoprecipitation
Rabbit IgG/IgM Dynabeads (Invitrogen) were washed three times with 200 µL of Blocking Buffer (0.5 % BSA, 0.2 % Fish Skin Gelatin in PBS; pH was adjusted to 7.4) to block non-specific binding sites. During each wash, beads were gently mixed by rotation for five minutes. Beads were then pulled down with a magnet for one minute and the supernatant was removed and replaced with fresh blocking buffer. Dynabeads were incubated with either rabbit anti-α1D-adrenoreceptor antibody (Alomone, 1:30) or rabbit anti-Panx1 CT-395 antibody (1:50) overnight at 4°C. Antibodies were conjugated to Dynabeads by washing twice with conjugation buffer (Sodium phosphate 20 mmol/L, NaCl 150 mmol/L, pH adjusted to 7.4) followed by incubation with 5 mmol/L BS 3 (Thermo Scientific) in conjugation buffer and a final wash with Quenching Buffer (1mol/L Tris-HCl, pH adjusted to 7.4). Beads were then washed three times with blocking buffer and stored at 4°C until use. Protein extracts from TDA were prepared as described above in the western blot section. Protein extracts from TDA were incubated with antibody-conjugated Dynabeads for 2 hours at 4°C on tube rotator. The beads were then pulled down with a magnet and washed twice with lysis buffer for 15 minutes followed by a final wash with PBS at 4°C. Beads were then pulled down with a magnet, resuspended in Laemmli buffer and incubated for 10 minutes at room temperature to remove bound proteins. Samples were subjected to SDS-PAGE, transferred to nitrocellulose and labeled with either rabbit anti-α1D-adrenoreceptor antibody (1:250) or Rabbit antiPannexin 1 CT-395 antibody (1:250).
ATP assay
Primary mouse aortic smooth muscle cells and human coronary smooth muscle cells (Lonza) were grown in DMEM F12 supplemented with 10%. Normal rat kidney cells (NRK) were cultured in DMEM high glucose supplemented with 10% FBS. Cells were placed in DMEM supplemented with 1 % BSA one hour before the experiment to prevent further ATP degradation by FBS. Cells were treated for 5 minutes with the pannexin inhibitors 10 Panx1 (300 µM) prior to stimulation with 10 -4 M PE. The media were collected 15 minutes after 10 -4 PE and 50 µL of the media was mixed with 50 µL of CellTiter-Glo reagent
